Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blood Pressure Level and Variability During Long-Term Prasugrel or Clopidogrel Medication After Stroke: PRASTRO-I.
Toyoda K, Yamagami H, Kitagawa K, Kitazono T, Nagao T, Minematsu K, Uchiyama S, Tanahashi N, Matsumoto M, Nagata I, Nishikawa M, Nanto S, Shirai T, Abe K, Ikeda Y, Ogawa A; PRASTRO Trial Investigators*. Toyoda K, et al. Among authors: nanto s. Stroke. 2021 Apr;52(4):1234-1243. doi: 10.1161/STROKEAHA.120.032824. Epub 2021 Feb 10. Stroke. 2021. PMID: 33563017 Free article. Clinical Trial.
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S; PRASFIT-Elective Investigators. Isshiki T, et al. Among authors: nanto s. Circ J. 2014;78(12):2926-34. doi: 10.1253/circj.cj-14-0266. Epub 2014 Oct 21. Circ J. 2014. PMID: 25342212 Free article. Clinical Trial.
Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Ikeda Y, Saito S. Nakamura M, et al. Among authors: nanto s. Int J Cardiol. 2015 Mar 1;182:541-8. doi: 10.1016/j.ijcard.2015.01.026. Epub 2015 Jan 8. Int J Cardiol. 2015. PMID: 25679803 Free article.
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S. Ogawa H, et al. Among authors: nanto s. J Cardiol. 2016 Jul;68(1):29-36. doi: 10.1016/j.jjcc.2015.07.019. Epub 2015 Oct 29. J Cardiol. 2016. PMID: 26521100 Free article. Clinical Trial.
A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.
Nagao T, Toyoda K, Kitagawa K, Kitazono T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu K, Nagata I, Nishikawa M, Nanto S, Abe K, Ikeda Y, Ogawa A. Nagao T, et al. Among authors: nanto s. Expert Opin Pharmacother. 2018 Apr;19(6):529-535. doi: 10.1080/14656566.2018.1444029. Epub 2018 Mar 26. Expert Opin Pharmacother. 2018. PMID: 29463150 Clinical Trial.
Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I).
Ogawa A, Toyoda K, Kitagawa K, Kitazono T, Nagao T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu K, Nagata I, Nishikawa M, Nanto S, Abe K, Ikeda Y; PRASTRO-I Study Group. Ogawa A, et al. Among authors: nanto s. Lancet Neurol. 2019 Mar;18(3):238-247. doi: 10.1016/S1474-4422(18)30449-6. Epub 2019 Feb 12. Lancet Neurol. 2019. PMID: 30784555 Clinical Trial.
Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.
Kitazono T, Toyoda K, Kitagawa K, Nagao T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu K, Nagata I, Nishikawa M, Nanto S, Ikeda Y, Shirai T, Abe K, Ogawa A; PRASTRO-I Study Group. Kitazono T, et al. Among authors: nanto s. J Atheroscler Thromb. 2021 Feb 1;28(2):169-180. doi: 10.5551/jat.56093. Epub 2020 Jun 4. J Atheroscler Thromb. 2021. PMID: 32493881 Free PMC article. Clinical Trial.
Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction.
Matsumoto S, Nakatani D, Sakata Y, Suna S, Shimizu M, Usami M, Hara M, Sumitsuji S, Nanto S, Sasaki T, Hamasaki T, Sato H, Hori M, Komuro I; Osaka Acute Coronary Insufficiency Study (OACIS) Group. Matsumoto S, et al. Among authors: nanto s. Circ J. 2013;77(4):1026-32. doi: 10.1253/circj.cj-12-0999. Epub 2012 Dec 29. Circ J. 2013. PMID: 23291993 Free article. Clinical Trial.
282 results